risks of glp-1 Agonists In Obesity Long-Term Risks of GLP-1 Drugs:

Moreover, the inhibitory impact of Liraglutide on NF-B/MAPK-NFATc1 was nullified when GLP-1R was eliminated

This aligns with research indicating diminishing returns with long-term GLP-1 use

6, A399A400

For current practice, the most defensible use of GLP-1RAs is as a time-bounded metabolic optimization strategy in women with meaningful obesity/insulin-resistance burden, with reproductive endpoints interpreted as potential downstream gains rather than guaranteed direct effects (111, 112, 124)

GET FOX BUSINESS ON THE GO BY CLICKING HERE The two companies are facing competition from cheaper compounded versions of the drugs offered by telehealth platforms like Hims & Hers, which are permitted to make and sell the drugs in personalized doses or composition